Literature DB >> 23459474

Cytosporone B, an inhibitor of the type III secretion system of Salmonella enterica serovar Typhimurium.

Jianfang Li1, Chao Lv, Weiyang Sun, Zhenyu Li, Xiaowei Han, Yaoyao Li, Yuemao Shen.   

Abstract

Bacterial virulence factors have been increasingly regarded as attractive targets for development of novel antibacterial agents. Virulence inhibitors are less likely to generate bacterial resistance, which makes them superior to traditional antibiotics that target bacterial viability. Salmonella enterica serovar Typhimurium, an important food-borne human pathogen, has type III secretion system (T3SS) as its major virulence factor. T3SS secretes effector proteins to facilitate invasion into host cells. In this study, we identified several analogs of cytosporone B (Csn-B) that strongly block the secretion of Salmonella pathogenicity island 1 (SPI-1)-associated effector proteins, without affecting the secretion of flagellar protein FliC in vitro. Csn-B and two other derivatives exhibited a strong inhibitory effect on SPI-1-mediated invasion to HeLa cells, while no significant toxicity to bacteria was observed. Nucleoid proteins Hha and H-NS bind to the promoters of SPI-1 regulator genes hilD, hilC, and rtsA to repress their expression and consequently regulate the expression of SPI-1 apparatus and effector genes. We found that Csn-B upregulated the transcription of hha and hns, implying that Csn-B probably affected the secretion of effectors through the Hha-H-NS regulatory pathway. In summary, this study presented an effective SPI-1 inhibitor, Csn-B, which may have potential in drug development against antibiotic-resistant Salmonella.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23459474      PMCID: PMC3632957          DOI: 10.1128/AAC.02421-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  62 in total

1.  A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis.

Authors:  Sandra Muschiol; Leslie Bailey; Asa Gylfe; Charlotta Sundin; Kjell Hultenby; Sven Bergström; Mikael Elofsson; Hans Wolf-Watz; Staffan Normark; Birgitta Henriques-Normark
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

Review 2.  The functional interface between Salmonella and its host cell: opportunities for therapeutic intervention.

Authors:  Jayesh C Patel; Olivia W Rossanese; Jorge E Galán
Journal:  Trends Pharmacol Sci       Date:  2005-09-22       Impact factor: 14.819

3.  Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle.

Authors:  Leslie Bailey; Asa Gylfe; Charlotta Sundin; Sandra Muschiol; Mikael Elofsson; Peter Nordström; Birgitta Henriques-Normark; Raimond Lugert; Anders Waldenström; Hans Wolf-Watz; Sven Bergström
Journal:  FEBS Lett       Date:  2007-01-17       Impact factor: 4.124

4.  Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle.

Authors:  K Wolf; H J Betts; B Chellas-Géry; S Hower; C N Linton; K A Fields
Journal:  Mol Microbiol       Date:  2006-09       Impact factor: 3.501

Review 5.  Targeting virulence for antibacterial chemotherapy: identifying and characterising virulence factors for lead discovery.

Authors:  Andrea Marra
Journal:  Drugs R D       Date:  2006

6.  H-NS is a part of a thermally controlled mechanism for bacterial gene regulation.

Authors:  Shusuke Ono; Martin D Goldberg; Tjelvar Olsson; Diego Esposito; Jay C D Hinton; John E Ladbury
Journal:  Biochem J       Date:  2005-10-15       Impact factor: 3.857

7.  PhoP-induced genes within Salmonella pathogenicity island 1.

Authors:  Andrés Aguirre; María Laura Cabeza; Silvana V Spinelli; Michael McClelland; Eleonora García Véscovi; Fernando C Soncini
Journal:  J Bacteriol       Date:  2006-10       Impact factor: 3.490

8.  Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron.

Authors:  Anatoly Slepenkin; Per-Anders Enquist; Ulrik Hägglund; Luis M de la Maza; Mikael Elofsson; Ellena M Peterson
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

9.  Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium.

Authors:  Aurel Negrea; Eva Bjur; Sofia Eriksson Ygberg; Mikael Elofsson; Hans Wolf-Watz; Mikael Rhen
Journal:  Antimicrob Agents Chemother       Date:  2007-06-04       Impact factor: 5.191

10.  Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors.

Authors:  Debra L Hudson; Abigail N Layton; Terry R Field; Alison J Bowen; Hans Wolf-Watz; Mikael Elofsson; Mark P Stevens; Edouard E Galyov
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

View more
  19 in total

1.  New diketopiperazine derivatives with cytotoxicity from Nocardiopsis sp. YIM M13066.

Authors:  Mingwei Sun; Xiaotong Chen; Wenjun Li; Chunhua Lu; Yuemao Shen
Journal:  J Antibiot (Tokyo)       Date:  2017-04-05       Impact factor: 2.649

2.  Aspergone, a new chromanone derivative from fungus Aspergillus sp. SCSIO41002 derived of mangrove soil sample.

Authors:  Bin Yang; Huaming Tao; Xiao-Chu Qin; Zhen Wang; Junde Dong; Xiuping Lin; Xuefeng Zhou; Jian-Lin Li; Zheng-Chao Tu; Yonghong Liu
Journal:  J Antibiot (Tokyo)       Date:  2017-01-25       Impact factor: 2.649

3.  Novel Noncompetitive Type Three Secretion System ATPase Inhibitors Shut Down Shigella Effector Secretion.

Authors:  Heather B Case; Dominic S Mattock; Bill R Miller; Nicholas E Dickenson
Journal:  Biochemistry       Date:  2020-06-30       Impact factor: 3.162

4.  Shutting Down Shigella Secretion: Characterizing Small Molecule Type Three Secretion System ATPase Inhibitors.

Authors:  Heather B Case; Dominic S Mattock; Nicholas E Dickenson
Journal:  Biochemistry       Date:  2018-12-05       Impact factor: 3.162

5.  Piperine treatment suppresses Helicobacter pylori toxin entry in to gastric epithelium and minimizes β-catenin mediated oncogenesis and IL-8 secretion in vitro.

Authors:  Nagendran Tharmalingam; Min Park; Min Ho Lee; Hyun Jun Woo; Hyun Woo Kim; Ji Yeong Yang; Ki-Jong Rhee; Jong-Bae Kim
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

6.  The bacterial type III secretion system as a target for developing new antibiotics.

Authors:  Andrew C McShan; Roberto N De Guzman
Journal:  Chem Biol Drug Des       Date:  2015-01       Impact factor: 2.817

7.  Identification of Translocation Inhibitors Targeting the Type III Secretion System of Enteropathogenic Escherichia coli.

Authors:  Sabrina Mühlen; Viktor A Zapol'skii; Ursula Bilitewski; Petra Dersch
Journal:  Antimicrob Agents Chemother       Date:  2021-09-20       Impact factor: 5.191

8.  Developing Cyclic Peptomers as Broad-Spectrum Type III Secretion System Inhibitors in Gram-Negative Bacteria.

Authors:  Hanh N Lam; Tannia Lau; Adam Lentz; Jessica Sherry; Alejandro Cabrera-Cortez; Karen Hug; Annalyse Lalljie; Joanne Engel; R Scott Lokey; Victoria Auerbuch
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.938

Review 9.  New therapeutic approaches for treatment of tularaemia: a review.

Authors:  Sandrine Boisset; Yvan Caspar; Vivien Sutera; Max Maurin
Journal:  Front Cell Infect Microbiol       Date:  2014-03-28       Impact factor: 5.293

10.  Encyclopedia of bacterial gene circuits whose presence or absence correlate with pathogenicity--a large-scale system analysis of decoded bacterial genomes.

Authors:  Maksim Shestov; Santiago Ontañón; Aydin Tozeren
Journal:  BMC Genomics       Date:  2015-10-13       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.